RxDoctor Payments Data

Diane Nguyen, MD

Family Medicine · Westminster, CANPI 1225065428

Payments from drug & device makers

$20,245in general payments, 2019–2025

Across 399 payments — averaging $50.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • AstraZeneca$3K
  • Lilly USA, LLC$2K
  • Gilead$2K
  • GSK$1K
  • Boehringer Ingelheim$901
  • plus $8K from 43 others

What the payments were for

  • Speaking & faculty fees$1251%
  • Travel & lodging$30%
  • Food & beverage$20,11799%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,245 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$32,415
Medicare patients
100
Services billed
390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin56$57,595
Diclofenac Sodium66$44,235
KerendiaFinerenone35$30,011
Cyclosporine39$28,814
FarxigaDapagliflozin Propanediol21$20,050
EliquisApixaban23$15,397
Tacrolimus25$10,464
JanuviaSitagliptin Phosphate12$10,098
VascepaIcosapent Ethyl28$10,009
Icosapent Ethyl24$7,850
Albuterol Sulfate HfaAlbuterol Sulfate58$2,542
Atorvastatin Calcium218$2,047
Alendronate Sodium175$1,519
Colchicine15$1,036
Amlodipine Besylate185$936

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$901$57,59556 claims
BayerKerendia$374$30,01135 claims
AstraZenecaFarxiga$2,742$20,05021 claims
PfizerEliquis$75$15,39723 claims
MerckJanuvia$501$10,09812 claims
Scilex Pharmaceuticals Inc.Colchicine$277$1,03615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Westminster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →